Knowledge & insights

banner-image
banner-image
banner-image

 

Knowledge & insights

banner-image
banner-image
banner-image

Stay competitive and maintain an admired company culture.

Role of Oral Fluid in Federally Mandated Workplace Drug Testing

eReader™+ is the next generation in instrument-interpreted screening.

If you feel hiring has become more competitive, you’re not alone. According to Forbes, 54% of companies report talent shortages—the highest in over a decade.1  With more jobs available than people to fill them, qualified candidates may have the luxury of entertaining multiple offers. When you find the right potential employee, the last thing you want is to lose them to another company.

Your drug screening solution is one way to boost your chances of landing the right talent. After all, when you get drug results faster—and clear candidates quickly—you may have a viable advantage over companies that can’t.

Supporting a healthy, productive and engaged workforce.

Employees with healthy habits are 3.1 times more productive2, according to the World Economic Forum and the Harvard School of Public Health. Clearly, managing the safety and health of your employees can be an important investment for your business—and drug and alcohol abuse can be challenges to workplace productivity and safety.

Managing the safety and health of your employees

"managing the safety and health of your employees can be an important investment for your business"

Putting substance abuse testing services in place can be a key step toward helping you achieve an admired drug-safe workplace and setting your business up for success. And safe, healthy, productive employees can help build and maintain the success of a company and its communities.

Why an instrumented expanded panel solution might be the choice for you.

The eScreen eReader+ solution helps give businesses—large and small—the ability to manage their employee drug testing. The eReader+ system helps your business get the results you need. It screens for up to 13 of the most common drugs of abuse, and gives you the flexibility to choose from panel options based on your needs and policies.

  • It’s streamlined for HR—The process is an entirely digital experience for employers, from ordering the test to getting the result. You can track the progress of each applicant’s test much like you would track an online purchase.
  • It’s accurate for better-informed decisions— eReader+ technology tests, reads, and reports results while maintaining confidentiality, precision, and consistency and removing the subjectivity of human read results.
  • It’s convenient for job candidates—Candidates can choose the clinic that’s most convenient to them. They can select from thousands of connected clinics where businesses are located across the U.S.
  • It’s fast for timely hiring decisions—eReader+ scans and interprets  a negative result in as little as 3 minutes. If the test is non-negative, it’s sent to the lab for further analysis.

Innovative technology aside, the eReader+ solution is provided through an expansive nationwide network. When you order a test, each prospective employee receives an electronic passport for check-in at the clinic. Within minutes of taking their test, you’ll have the electronic results available through your MyeScreen™ portal.3

Helping you make the right hiring decisions quickly.

Visit escreen.com to learn more about how eScreen and the eReader+ system can support your drug-safe workplace.

References

https://www.forbes.com/sites/carolinecastrillon/2021/09/22/why-us-talent-shortages-are-at-a-ten-year-high/?sh=1472580879c2

https://business.inquirer.net/81028/employee-wellness-can-translate-to-more-profit

Negative results are reported automatically in as little as 3 minutes. Non-negative samples are sent to the laboratory for confirmatory testing, and then on to an independent medical review officer (MRO) for final determination. All results are provided electronically through the MyeScreen employer portal.

This content is intended for general information purposes only. Abbott makes no representations or warranties regarding the content of this article, including as to the accuracy or completeness.

Select a topic

Related Articles

©2024 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.

Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy.

Abbott - A Global Leader in Toxicology.

Please click "Accept Sale/Sharing and Targeted Advertising" to enable full site functionality.

At this time, we are experiencing problems with broken links on our site. As an interim solution, for full site functionality you must enable functional and advertising cookies. If you continue to opt-out of these cookies, some content on our site may not be viewable.

We use functional cookies to analyze your use of the site, improve performance and provide a better customer experience. We use advertising cookies to allow us, through certain data assigned and obtained from the user's device, to store or share with third parties information related to user's browsing activity in our website, in order to create an advertising profile and place relevant advertising in our website or those third parties websites. For more information about how Abbott uses cookies please see our Cookie Policy and Privacy Policy.

In order to accept functional and advertising cookies, please click "Enable Cookies" and then click "Accept Sale/Sharing and Targeted Advertising" to view the full site.

COLLAPSE
Learn more about cookies